Carlson Capital L P lifted its position in Johnson & Johnson (NYSE:JNJ) by 21.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,320 shares of the company’s stock after purchasing an additional 27,146 shares during the quarter. Carlson Capital L P’s holdings in Johnson & Johnson were worth $21,076,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Zions Bancorporation N.A. increased its position in Johnson & Johnson by 0.4% during the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after buying an additional 73 shares in the last quarter. Cambridge Advisors Inc. increased its position in Johnson & Johnson by 0.3% during the 4th quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after buying an additional 78 shares in the last quarter. Vishria Bird Financial Group LLC increased its position in Johnson & Johnson by 3.0% during the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after buying an additional 80 shares in the last quarter. Burt Wealth Advisors boosted its stake in Johnson & Johnson by 0.6% during the 4th quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock valued at $1,665,000 after purchasing an additional 82 shares during the last quarter. Finally, Timber Creek Capital Management LLC boosted its stake in Johnson & Johnson by 8.7% during the 4th quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock valued at $133,000 after purchasing an additional 83 shares during the last quarter. Hedge funds and other institutional investors own 72.01% of the company’s stock.
Shares of JNJ opened at $128.60 on Friday. The firm has a market capitalization of $345.70 billion, a PE ratio of 15.72, a price-to-earnings-growth ratio of 2.22 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company’s fifty day moving average price is $130.05 and its 200-day moving average price is $135.44.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period in the prior year, the company earned $2.10 earnings per share. The firm’s revenue was down 1.3% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.95%. The ex-dividend date was Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.
Several analysts have commented on JNJ shares. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Barclays assumed coverage on Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price target on the stock. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Bank of America reaffirmed a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $150.60.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How to Invest in Growth Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.